文献速递心外重症与机械循环支持

STS Intermacs 持久性左心室辅助装置植入90天死亡风险模型在扩展当代队列中的验证

STS Intermacs 90-Day Mortality Risk Model for Durable Left Ventricular Assist Device Implant: Validation in an Expanded Contemporary Cohort.
PubMed 文献 · Ann Thorac Surg · 2026-09-16

本研究旨在验证STS Intermacs持久性左心室辅助装置(LVAD)植入90天死亡风险模型在扩展当代患者队列中的性能。模型重新拟合后,区分度(AUC 0.6963 vs 0.6928)和校准度(Brier评分0.074 vs 0.075)保持稳定。结论认为该模型在扩展队列中保持可接受的性能,支持其用于候选者选择、基准评估和质量评估。

要点

  • STS Intermacs 90天死亡风险模型在超过15,000例扩展队列中区分度和校准度保持稳定。
  • 模型重新拟合后AUC为0.6963 vs 0.6928,Brier评分为0.074 vs 0.075。

核心结论

  • STS Intermacs 90天死亡风险模型在扩展当代队列中保持可接受的性能。
  • 模型区分度和校准度的稳定性支持其作为高危患者候选者选择、基准评估和质量评估的稳健工具。

研究设计与样本

  • 研究查询STS Intermacs数据库,纳入2019年1月1日至2025年3月31日期间接受初次左心室辅助装置植入的患者。
  • 模型性能通过区分度和校准度指标评估。

主要发现

  • 与新验证队列相比,原始队列患者白人比例更高(58.6% vs 54.4%,P<.0001),既往冠状动脉旁路移植术比例更高(13.9% vs 11.0%,P<.0001)。
  • 新验证队列糖尿病比例更高(16.4% vs 12.6%,P<.0001),需要伴随手术的比例更高(58.1% vs 51.8%,P<.0001)。
  • 新验证队列血清谷草转氨酶/天冬氨酸氨基转移酶(36.7 vs 41.0 IU/L,P=.003)、血尿素氮(27.5 vs 28.1 mg/dL,P=.02)和胆红素(1.1 vs 1.2 mg/dL,P<.0001)水平更低。
  • 两队列90天死亡率相似(P=.99)。
  • 模型重新拟合后,应用于原始完整队列(推导)和新当代验证队列的逻辑回归产生相似的区分度(AUC 0.6963 vs 0.6928)和校准度(Brier评分0.074 vs 0.075)。

临床怎么用

  • 该模型可用于持久性左心室辅助装置候选者选择、中心性能基准评估和质量改进。
  • 临床医生可参考该模型评估高危患者90天死亡风险,辅助决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mortality risk models for durable left ventricular assist device implantation inform candidate selection, provider performance, and quality improvement. We sought to validate (STS) Intermacs mortality risk model in an expanded contemporary patient cohort. METHODS: STS Intermacs was queried for patients undergoing primary left ventricular assist device implantation between January 1, 2019, and March 31, 2025. Beyond the original derivation and validation cohorts (N = 11,342), 4344 additional eligible patients who underwent implantation between October 1, 2023, and March 31, 2025, were identified, yielding an expanded study population of 15,686 implants. Model performance was evaluated using measures of discrimination and calibration. RESULTS: Compared with the original cohort, patients in the new validation cohort were less likely to be White (54.4% vs 58.6%, P < .0001); have prior coronary artery bypass grafting (11.0% vs 13.9%, P < .0001); more likely to have diabetes (16.4% vs 12.6%, P < .0001); require concomitant surgery (58.1% vs 51.8%, P < .0001); and have lower levels of serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (36.7 vs 41.0 IU/L, P = .003), blood urea nitrogen (27.5 vs 28.1 mg/dL, P = .02), and bilirubin (1.1 vs 1.2 mg/dL, P < .0001). Ninety-day mortality was similar between cohorts (P = .99). After model refitting to account for significant baseline differences, logistic regression applied to the original full cohort (derivation) and new contemporary validation cohort produced similar discrimination (area under the curve, 0.6963 vs 0.6928) and calibration (Brier score, 0.074 vs 0.075). CONCLUSIONS: STS Intermacs 90-day mortality risk model maintains acceptable performance when applied to an expanded cohort. The stability of discrimination and calibration in >15,000 patients support its use as a robust tool for candidate selection, benchmarking, and quality assessment in a high-risk patient population.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Molina EJ, Wood K, Cantor RS, et al. STS Intermacs 90-Day Mortality Risk Model for Durable Left Ventricular Assist Device Implant: Validation in an Expanded Contemporary Cohort. Ann Thorac Surg. 2026. PMID: 42744129. doi:10.1016/j.athoracsur.2026.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。